Menu
Not yet recruiting NCT07520812

Impact of Exercise Training on Serum Neurofilament Light Chain (NfL), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis

No phase Interventional Multiple Sclerosis Exercise Neurofilament Light Chain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Exercise.
Who it may be relevant to
Registry conditions: Multiple Sclerosis, Exercise, Neurofilament Light Chain. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effect of an Exercise Intervention on Serum Neurofilament Light Chain and Brain Volumetry in Patients With Multiple Sclerosis: A Randomized Controlled Trial

Overview

This single-blind, randomized controlled trial will employ a two-arm parallel design (exercise group vs. control group) with a 12-week intervention period. Randomization will be implemented using SPSS 25.0 (IBM Corporation, Armonk, NY, USA) to ensure balanced group allocation. All outcome measures will be assessed at baseline and post-intervention.

Detailed description

The exercise intervention will consist of supervised progressive resistance training sessions conducted three times weekly (with a minimum 48-hour rest period between sessions) at Firat University Hospital. Control participants will maintain their usual daily activities without participating in any structured exercise programs.A blinded neurologist will perform all clinical assessments to eliminate measurement bias. To control for circadian variations, all evaluations will be scheduled at consistent times of day for each participant. Environmental conditions will be strictly maintained during testing sessions (ambient temperature: 21-22°C; humidity: 55-60%). This study will be designed and reported in accordance with CONSORT guidelines for randomized trials, incorporating all essential elements for transparent randomized controlled reporting, including allocation concealment, blinding procedures, and intention-to-treat principles.

Interventions

  • Other Exercise
    According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minute sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period

Primary outcome measures

  • MRI Acquisition and Volumetric Analysis [Time frame: 12 weeks]
  • Serum Neurofilament Light Chain (NfL) measurement [Time frame: 12 Weeks]
Secondary outcome measures (5)
  • Multiple Sclerosis Functional Composite [Time frame: 12 Weeks]
  • Fatigue Impact Scale [Time frame: 12 Weeks]
  • Short form-12 version 2 (SF-12v2) [Time frame: 12 Weeks]
  • Problem-Solving inventory (PSI) [Time frame: 12 Weeks]
  • Emotional intelligence scale (EIS) [Time frame: 12 Weeks]

Eligibility criteria

Inclusion criteria

  • Clinically confirmed relapsing-remitting multiple sclerosis (RRMS) diagnosis according to revised McDonald criteria (2017)
  • Mild-to-moderate disability (EDSS score 1.0-5.5)
  • No corticosteroid treatment within the previous 3 months

Exclusion criteria

  • Acute MS relapse within 90 days prior to enrollment
  • Regular participation in structured exercise programs (>3 hours/week)
  • Comorbid conditions that may limit exercise participation, including; significant orthopedic impairments, unstable cardiopulmonary conditions and other systemic disorders affecting physical activity
  • Standard MRI contraindications (metallic implants, claustrophobia, etc.)
  • Concurrent neurological disorders (other than MS)
  • Initiation or modification of disease-modifying therapy within 6 months
  • Severe spasticity (Modified Ashworth Scale ≥3 in any major muscle group)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Turkey (Türkiye) · 1 center
  • Fırat University — Elâzığ

Identifiers

NCT: NCT07520812 · 234823

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗